Suppr超能文献

射频消融治疗骨样骨瘤-复发率和预测因素。

Radiofrequency ablation for osteoid osteoma - Recurrence rates and predictive factors.

机构信息

Department of Orthopaedic Oncology, Glasgow Royal Infirmary, Castle Street, Glasgow, G4 0ET, UK.

Wolfson Medical School, University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK.

出版信息

Surgeon. 2018 Jun;16(3):156-162. doi: 10.1016/j.surge.2017.07.001. Epub 2017 Aug 12.

Abstract

BACKGROUND AND PURPOSE

Osteoid osteoma is an infrequent but debilitating benign bone lesion which can be successfully managed by percutaneous radiofrequency ablation (RFA). There are few studies investigating the efficacy and follow-up of this treatment. An arbitrary upper limit of 15 mm has been used to differentiate between osteoid osteoma and osteoblastoma with surgery used for lesions above this limit. We aimed to analyse the cases identified from our prospectively maintained database over a ten year period since adoption of this technique in our unit. The primary objectives were to investigate factors which influenced recurrence and the time period at which patients are at risk of this.

BASIC PROCEDURES

Consecutive patients with confirmed osteoid osteoma were included. Patient demographics, complications, and recurrence were recorded and multiple regression analysis was performed to investigate causation.

MAIN FINDINGS

Within a minimum follow up of 21 months (mean 72), a recurrence rate of 16.3% was noted, higher than the published literature. Cox regression analysis to predict chance of recurrence revealed a relationship between larger lucent diameter and recurrence (p = 0.049, CI 95%, hazard ratio 1.33).

CONCLUSIONS

The traditional cut off between osteoid osteoma and osteoblastoma appears less rigidly defined than previously thought and probably represents a progressive scale with larger lesions responding less well to RFA. This study indicates that each millimetre increase represents a ×1.33 chance of recurrence. Clinicians should counsel patients accordingly with lesions approaching the larger limits of this diagnosis.

摘要

背景与目的

骨样骨瘤是一种罕见但使人虚弱的良性骨病变,经皮射频消融(RFA)可成功治疗。目前关于该治疗方法的疗效和随访的研究较少。为了与手术治疗区分,传统上使用 15mm 作为骨样骨瘤和骨母细胞瘤的界限,对于大于该界限的病变则采用手术治疗。我们旨在分析自采用该技术以来,在我们单位 10 年期间前瞻性维护数据库中确定的病例。主要目的是研究影响复发的因素及其易复发的时间。

基本程序

纳入经证实的骨样骨瘤连续患者。记录患者的人口统计学资料、并发症和复发情况,并进行多因素回归分析以探讨病因。

主要发现

在至少 21 个月(平均 72 个月)的随访中,复发率为 16.3%,高于已发表的文献报道。Cox 回归分析预测复发的机会显示,透亮直径越大与复发之间存在相关性(p=0.049,95%CI,风险比 1.33)。

结论

传统上骨样骨瘤和骨母细胞瘤的界限似乎不如以前认为的那么严格,可能代表一个逐渐发展的过程,较大的病变对 RFA 的反应较差。本研究表明,每个毫米的增加代表复发的几率增加 1.33 倍。临床医生应相应地告知接近该诊断较大界限的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验